Amicus Therapeutics

Quarterly Financials

Values in thousands 2024-09-30 2024-06-30 2024-03-31 2023-12-31
Revenue
$141,517
$126,669
$110,403
$115,082
Gross Profit
128,238
113,226
94,682
101,576
EBITDA
21,647
14,802
-28,993
-16,651
EBIT
19,477
12,620
-31,147
-18,833
Net Income
-6,729
-15,697
-48,419
-33,843
Net Change In Cash
141,517
126,669
110,403
115,082
Free Cash Flow
9,913
21,593
-31,506
1,727
Cash
233,647
209,335
209,761
246,994
Basic Shares
304,690
303,773
302,903
293,594

Annual Financials

Values in thousands 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Revenue
$399,356
$329,233
$305,514
$260,886
Gross Profit
362,030
290,634
271,048
229,842
EBITDA
-92,079
-199,578
-202,874
-242,983
EBIT
-99,952
-204,920
-209,083
-251,829
Net Income
-151,584
-236,568
-250,460
-276,852
Net Change In Cash
399,356
329,233
305,514
260,886
Cost of Revenue
-81,722
88,343
15,989
Free Cash Flow
-76,531
-170,341
-206,375
-236,517
Cash
246,994
148,813
245,197
163,240
Basic Shares
295,164
289,057
271,421
258,867

Earnings Calls

Quarter EPS
2024-09-30
-$0.02
2024-06-30
-$0.05
2024-03-31
-$0.16
2023-12-31
-$0.11